



Addressing Severe Allergic Asthma: Why Effective Treatment Matters

王恭仰
亞東醫院



Conclusions

- Environment change might lead the increasing of allergic disease, including allergic asthma.
- Considered allergic asthma and perennial allergy first for biological agent selection in severe asthma.
- Proposed “anti-IgE prioritized” algorithms for severe asthma with overlapping (allergic + eosinophilic) phenotype.
- Omalizumab is the only biologic with proven antiviral action against viruses responsible for upper respiratory tract infections and asthma exacerbations
- Xolair® is the only biologic with long-term data to demonstrate the efficacy and safety
- Xolair® showed a marked OCS-sparing capacity and long-term improvement of FEV1.
- Airway remodeling reversed and improved epithelial damage in patients with severe asthma after Xolair® treatment.